Degenerative Disc Disease – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Degenerative Disc Disease – Pipeline Review, H2 2017’, provides an overview of the Degenerative Disc Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Degenerative Disc Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease

The report reviews pipeline therapeutics for Degenerative Disc Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Degenerative Disc Disease therapeutics and enlists all their major and minor projects

The report assesses Degenerative Disc Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Degenerative Disc Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AnGes MG Inc

Biopharm GmbH

BioRestorative Therapies Inc

Bone Therapeutics SA

DiscGenics Inc

Osiris Therapeutics Inc

Samumed LLC

TissueGene Inc

U.S. Stem Cell Inc

Yuhan Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Degenerative Disc Disease - Overview

Degenerative Disc Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Degenerative Disc Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Degenerative Disc Disease - Companies Involved in Therapeutics Development

AnGes MG Inc

Biopharm GmbH

BioRestorative Therapies Inc

Bone Therapeutics SA

DiscGenics Inc

Osiris Therapeutics Inc

Samumed LLC

TissueGene Inc

U.S. Stem Cell Inc

Yuhan Corp

Degenerative Disc Disease - Drug Profiles

AdipoCell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLOB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BRTX-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dibotermin alfa biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTICR-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly N-Acetyl Glucosamine Hydrogel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-04690 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Degenerative Disc Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Degenerative Disc Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Degenerative Disc Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-0002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-14618 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Degenerative Disc Disease - Dormant Projects

Degenerative Disc Disease - Product Development Milestones

Featured News & Press Releases

Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

Feb 08, 2017: BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease

Jan 09, 2017: BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease

Nov 15, 2016: Samumed Presents Data for a Small Molecule Modulator of Wnt Pathway as a Potential Treatment for Degenerative Disc Disease

Nov 01, 2016: Samumed to present data on SM-04690 at American College of Rheumatology 2016 Annual Meeting

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

Sep 12, 2016: BioRestorative Therapies Announces Publication in Medical Journal of Positive Results of Long-Term Safety and Feasibility Study Using Cell Therapy to Treat Patients with Degenerative Disc Disease

May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study

Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference

Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial

Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product

Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA

Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA

Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease

Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Degenerative Disc Disease, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Degenerative Disc Disease – Pipeline by AnGes MG Inc, H2 2017

Degenerative Disc Disease – Pipeline by Biopharm GmbH, H2 2017

Degenerative Disc Disease – Pipeline by BioRestorative Therapies Inc, H2 2017

Degenerative Disc Disease – Pipeline by Bone Therapeutics SA, H2 2017

Degenerative Disc Disease – Pipeline by DiscGenics Inc, H2 2017

Degenerative Disc Disease – Pipeline by Osiris Therapeutics Inc, H2 2017

Degenerative Disc Disease – Pipeline by Samumed LLC, H2 2017

Degenerative Disc Disease – Pipeline by TissueGene Inc, H2 2017

Degenerative Disc Disease – Pipeline by U.S. Stem Cell Inc, H2 2017

Degenerative Disc Disease – Pipeline by Yuhan Corp, H2 2017

Degenerative Disc Disease – Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development for Degenerative Disc Disease, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports